The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.
about
Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosisMolecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future DirectionsNeoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumabHER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesTargeted therapy for HER2 positive breast cancerDepletion of kinesin 5B affects lysosomal distribution and stability and induces peri-nuclear accumulation of autophagosomes in cancer cellsMolecular imaging agents: impact on diagnosis and therapeutics in oncologyKu proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines.Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers.ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.Poly (A)+ transcriptome assessment of ERBB2-induced alterations in breast cell lines.Anti-HER2 vaccines: new prospects for breast cancer therapyPossible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breastPleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output.Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3Detection of HER2 amplification in circulating free DNA in patients with breast cancer.Preoperative serum HER2 extracellular domain levels in primary invasive breast cancerThe Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy.Role of traditional and new biomarkers in breast carcinogenesis.Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study.Molecular Determinants of Prognosis in Hepatocellular Carcinoma.HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene.Potential Therapeutic Targets in Uterine Sarcomas.Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer.Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification.Biological markers and response to neoadjuvant taxane-based chemotherapy in patients with locally advanced breast cancer.A comparison of image contrast with (64)Cu-labeled long circulating liposomes and (18)F-FDG in a murine model of mammary carcinoma.Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapyComparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease.Role of hormonal risk factors in HER2-positive breast carcinomas.IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis.A gene expression profile indicative of early stage HER2 targeted therapy responseMultifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond.Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters.
P2860
Q24646799-F888004C-71B2-42E7-8FF0-D615C91B9CDEQ26741320-F170C8A0-7A60-4603-A209-9AA774FFC0E2Q26764879-9B29B70F-C688-4241-9DF6-F12D003F09CDQ26822730-50635486-4E1C-4018-9821-4C8FE85163F3Q26830496-3CA83238-C8CA-4728-8975-5235F8AD8981Q27355564-A6A4C310-4208-467C-8898-76ED8A7C8662Q30433423-D2F5CE9C-2516-4437-AF42-14CB4C8A91F4Q33627164-FABFFB6E-E369-4876-BD21-BF8F7494932FQ33676758-6946A536-06B8-43AC-901D-0C6958F649F2Q33750808-004F5ECD-33B6-4550-9CFC-E43C02E63332Q33811642-4E99B519-BA3D-451B-8A60-76CD1E5E12A3Q33952142-FC10ED26-A532-4DDC-A397-53D78F199216Q34105959-5D4E0456-4879-4F2F-9B36-14675396E771Q34240339-60D5B89E-6CBB-4501-A07B-5E1A35A01BB6Q34281240-29CF90F5-8645-4824-9DA3-BD1CDB294BE4Q34659512-D10E0736-D1BE-4ABB-A3AC-49BD8CF39EDDQ34806810-3837E14B-E4A9-4164-9338-AF5E90ADBACDQ34967515-CEA110FD-D73F-4A08-A177-488BB6914E78Q35005626-649271B4-DB89-4081-B131-435BE7505A0EQ35572905-06AB3CB3-79A9-4091-A155-78DCC20EC1A4Q35583904-DD4DBEC7-D708-4015-A866-3DB290CB01C4Q35893399-AE77F687-60FD-4424-A346-B993F6DB2BBFQ35905975-FF524298-2021-45D3-B6B9-FA51C2CBB12DQ36087126-AD8CB735-A36E-4008-AA70-AB6B3D92E904Q36098453-0CAB7F40-8211-4063-AF62-8150C110F9B9Q36245677-682EB316-BF9D-48FA-93EB-A6C331B7E46AQ36405652-44508D19-A015-4223-AED8-D5834521FADEQ36458747-B435EC4D-57AC-4E0E-B26A-96FFFC0FF1ABQ36505849-34A37631-A4DD-4283-8E7B-0664B7BF3293Q36533813-313D9608-2109-46D5-80A9-67A553573801Q36611996-5A8EDAF0-8C58-4979-BBCD-4C38D8FE0DBAQ36615272-654F6A36-9889-428B-B296-CDD98D85F23FQ36646681-C2F250CC-EEC9-462F-9B8F-950D16F3B974Q36671364-EEFD1E8E-537E-459B-A19C-87C229BE99B3Q36718403-7CF0EE40-338C-4AC2-B230-6F8500AC818BQ36757173-922A3A3B-FCC1-4F5A-B35B-DEE04EE447D6Q37049733-4692C571-83DA-4A61-81B1-98EB6A3C7521Q37089496-5E01395F-AF6C-47F6-92E7-F700472BB463Q37220528-986818D6-987A-49B6-8999-ADD30327B89FQ37302085-11F05A16-B9DB-4542-8526-4F5D3D9A7CD8
P2860
The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
The HER-2/neu Oncogene in Brea ...... actor, and Target for Therapy.
@ast
The HER-2/neu Oncogene in Brea ...... actor, and Target for Therapy.
@en
type
label
The HER-2/neu Oncogene in Brea ...... actor, and Target for Therapy.
@ast
The HER-2/neu Oncogene in Brea ...... actor, and Target for Therapy.
@en
prefLabel
The HER-2/neu Oncogene in Brea ...... actor, and Target for Therapy.
@ast
The HER-2/neu Oncogene in Brea ...... actor, and Target for Therapy.
@en
P1433
P1476
The HER-2/neu Oncogene in Brea ...... actor, and Target for Therapy.
@en
P2093
P304
P577
1998-01-01T00:00:00Z